SG11201506966RA - Extracellular matrix-binding synthetic peptidoglycans - Google Patents

Extracellular matrix-binding synthetic peptidoglycans

Info

Publication number
SG11201506966RA
SG11201506966RA SG11201506966RA SG11201506966RA SG11201506966RA SG 11201506966R A SG11201506966R A SG 11201506966RA SG 11201506966R A SG11201506966R A SG 11201506966RA SG 11201506966R A SG11201506966R A SG 11201506966RA SG 11201506966R A SG11201506966R A SG 11201506966RA
Authority
SG
Singapore
Prior art keywords
extracellular matrix
binding synthetic
synthetic peptidoglycans
peptidoglycans
binding
Prior art date
Application number
SG11201506966RA
Inventor
Alyssa Panitch
John Eric Paderi
Shaili Sharma
Katherine Allison Stuart
Nelda Marie Vazquez-Portalatin
Original Assignee
Symic Biomedical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Symic Biomedical Inc filed Critical Symic Biomedical Inc
Publication of SG11201506966RA publication Critical patent/SG11201506966RA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545Heterocyclic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/16Emollients or protectives, e.g. against radiation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4725Proteoglycans, e.g. aggreccan
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K9/00Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
SG11201506966RA 2013-03-15 2014-03-14 Extracellular matrix-binding synthetic peptidoglycans SG11201506966RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361798916P 2013-03-15 2013-03-15
PCT/US2014/029596 WO2014144969A1 (en) 2013-03-15 2014-03-14 Extracellular matrix-binding synthetic peptidoglycans

Publications (1)

Publication Number Publication Date
SG11201506966RA true SG11201506966RA (en) 2015-10-29

Family

ID=51537842

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201506966RA SG11201506966RA (en) 2013-03-15 2014-03-14 Extracellular matrix-binding synthetic peptidoglycans

Country Status (14)

Country Link
US (3) US9200039B2 (en)
EP (1) EP2970509B1 (en)
JP (1) JP6603650B2 (en)
KR (1) KR20150130419A (en)
AU (1) AU2014233537A1 (en)
BR (1) BR112015022917A2 (en)
CA (1) CA2903450A1 (en)
EA (1) EA201591454A1 (en)
HK (1) HK1220217A1 (en)
IL (1) IL241054A0 (en)
MX (1) MX2015012608A (en)
SG (1) SG11201506966RA (en)
WO (1) WO2014144969A1 (en)
ZA (1) ZA201506391B (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2280720T3 (en) 2008-03-27 2019-06-11 Purdue Research Foundation COLLAGEN BINDING SYNTHETIC PEPTIDOGLYCANES, MANUFACTURING AND PROCEDURE FOR USE
KR102006036B1 (en) 2011-05-24 2019-07-31 시믹 아이피, 엘엘씨 Hyaluronic acid-binding synthetic peptidoglycans, preparation, and methods of use
JP6603650B2 (en) 2013-03-15 2019-11-06 パーデュー・リサーチ・ファウンデーション Extracellular matrix-bound synthetic peptidoglycan
US10772931B2 (en) 2014-04-25 2020-09-15 Purdue Research Foundation Collagen binding synthetic peptidoglycans for treatment of endothelial dysfunction
CN106714820A (en) 2014-05-12 2017-05-24 普渡研究基金会 Selectin and icam/vcam peptide ligand conjugates
JP6516235B2 (en) * 2014-10-31 2019-05-22 国立大学法人富山大学 Chimeric protein and microglial activity inhibitor using the same
JP6693728B2 (en) * 2014-11-14 2020-05-13 興和株式会社 Novel functional peptide
WO2016100846A1 (en) 2014-12-19 2016-06-23 Northwestern University Thromboresistant-anticoagulant extracellular matrix
WO2016161333A2 (en) * 2015-04-01 2016-10-06 Purdue Research Foundation Compositions comprising bioconjugates
KR20180016988A (en) * 2015-04-17 2018-02-20 시믹 아이피, 엘엘씨 Bio conjugates and uses thereof
US10463745B2 (en) * 2015-05-12 2019-11-05 Northwestern University Materials for tissue regeneration
AU2017326009B2 (en) 2016-09-16 2020-11-12 Glycologix, Inc. Sulfated glycosaminoglycan biomaterials as proteoglycan mimics
EP3648774A4 (en) 2017-07-07 2021-04-21 Symic IP, LLC Synthetic bioconjugates
US11896642B2 (en) 2017-07-07 2024-02-13 Symic Holdings, Inc. Bioconjugates with chemically modified backbones
WO2019010485A1 (en) * 2017-07-07 2019-01-10 Symic Ip, Llc Treatment of fibrosis
WO2022256568A1 (en) * 2021-06-02 2022-12-08 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods and compositions for localization of growth factors

Family Cites Families (142)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683298A (en) 1985-01-10 1987-07-28 British Columbia Research Council Process for the preparation of aminated polysaccharide derivatives
US5547936A (en) 1985-06-17 1996-08-20 La Jolla Cancer Research Foundation Inhibition of cell migration with synthetic peptides
DE68926051T2 (en) 1988-12-20 1996-08-29 Jolla Cancer Res Found POLYPEPTIDE-POLYMER CONJUGATES WITH Wounds Healing Effect
FR2644066B1 (en) 1989-03-09 1994-05-13 Therapeutiques Substitutives STABILIZED COMPOSITIONS COMPRISING FGFS, PROCESS FOR OBTAINING THEM AND THERAPEUTIC, SURGICAL AND COSMETOLOGICAL APPLICATIONS
US5693625A (en) 1989-03-09 1997-12-02 Therapeutiques Substitutives Method of regenerating cells and tissues using functionalized dextrans
DE69230136T2 (en) 1991-01-14 2000-05-25 New York University New York CYTOKIN-INDUCED PROTEIN, TSG-6, HIS DNA AND USE
JP2901787B2 (en) 1991-07-15 1999-06-07 日本メジフィジックス株式会社 Nuclear magnetic resonance contrast agent
FR2718023B1 (en) 1994-03-30 1996-08-14 Paris Val Marne Universite Medicament and pharmaceutical composition for the treatment of lesions of the digestive tract.
JP4193917B2 (en) 1995-12-18 2008-12-10 アンジオデバイス インターナショナル ゲーエムベーハー Crosslinked polymer composition and method of use thereof
CA2299687C (en) 1997-08-04 2009-10-27 Bio Syntech Ltd. Temperature-controlled ph-dependant formation of ionic polysaccharide gels
US5997895A (en) 1997-09-16 1999-12-07 Integra Lifesciences Corporation Dural/meningeal repair product using collagen matrix
CA2307846A1 (en) 1997-11-21 1999-06-03 Genset S.A. Chlamydia pneumoniae genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
US7691829B2 (en) 1998-03-24 2010-04-06 Petito George D Composition and method for healing tissues
FR2781485B1 (en) 1998-07-21 2003-08-08 Denis Barritault BIOCOMPATIBLE POLYMERS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM
JP3103531B2 (en) 1998-09-30 2000-10-30 延也 柳内 Human urine-derived cell adhesion glycoprotein and method for producing the same
US6822071B1 (en) 1998-11-12 2004-11-23 The Regents Of The University Of California Polypeptides from Chlamydia pneumoniae and their use in the diagnosis, prevention and treatment of disease
US6703491B1 (en) 1999-03-17 2004-03-09 Exelixis, Inc. Drosophila sequences
US6864235B1 (en) 1999-04-01 2005-03-08 Eva A. Turley Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
US20090087878A9 (en) 1999-05-06 2009-04-02 La Rosa Thomas J Nucleic acid molecules associated with plants
US20110214206A1 (en) 1999-05-06 2011-09-01 La Rosa Thomas J Nucleic acid molecules and other molecules associated with plants
FR2794976B1 (en) 1999-06-16 2004-05-07 Solutions PHARMACEUTICAL COMPOSITIONS WITH HEALING OR ANTI-COMPLEMENTARY ACTION COMPRISING A DEXTRANE DERIVATIVE
EP1218027B1 (en) 1999-09-15 2010-01-20 The Bruce H. DeWoolfson Irrevocable Family Trust Composition for stabilizing corneal tissue during or after orthokeratological lens wear
FR2799465B1 (en) 1999-10-12 2004-02-13 Centre Nat Rech Scient PEPTIDES HAVING ACTIVITY TO STIMULATE IMMUNE RESPONSE AND TISSUE REGENERATION
ATE243049T1 (en) 1999-12-09 2003-07-15 Biosyntech Canada Inc MINERAL-POLYMER HYBRID COMPOSITION
US20030158302A1 (en) 1999-12-09 2003-08-21 Cyric Chaput Mineral-polymer hybrid composition
WO2002017955A1 (en) 2000-08-30 2002-03-07 University Of Delaware Delivery system for heparin-binding growth factors
AU2001286791A1 (en) 2000-08-31 2002-03-13 University Of Delaware Bioactive peptide for cell adhesion
AU2002211517A1 (en) 2000-10-04 2002-04-15 California Institute Of Technology Magnetic resonance imaging agents for in vivo labeling and detection of amyloid deposits
US20040091540A1 (en) 2000-11-15 2004-05-13 Desrosiers Eric Andre Method for restoring a damaged or degenerated intervertebral disc
US20040236092A1 (en) 2001-07-13 2004-11-25 Roman Dziarski Peptidologlycan recognition protein encoding nucleic acids and methods of use thereof
WO2003015615A2 (en) 2001-08-15 2003-02-27 Brown University Research Foundation Treatment of muscular dystrophies and related disorders
ES2357889T3 (en) 2001-11-15 2011-05-03 Piramal Healthcare (Canada) Limited COMPOSITION AND METHOD TO RETICULATE OR MODIFY HOMOGENALLY CHITOSANE IN NEUTRAL CONDITIONS.
US20090100536A1 (en) 2001-12-04 2009-04-16 Monsanto Company Transgenic plants with enhanced agronomic traits
US20090158452A1 (en) 2001-12-04 2009-06-18 Johnson Richard G Transgenic plants with enhanced agronomic traits
US20050108791A1 (en) 2001-12-04 2005-05-19 Edgerton Michael D. Transgenic plants with improved phenotypes
US20030220253A1 (en) 2002-03-08 2003-11-27 Lasser Gerald W. Inhibitors for use in hemostasis
US7666852B2 (en) 2002-04-22 2010-02-23 Agenta Biotechnologies, Inc. Wound and cutaneous injury healing with a nucleic acid encoding a proteoglycan polypeptide
JP2005185101A (en) 2002-05-30 2005-07-14 National Institute Of Agrobiological Sciences VEGETABLE FULL-LENGTH cDNA AND UTILIZATION THEREOF
US7862831B2 (en) 2002-10-09 2011-01-04 Synthasome, Inc. Method and material for enhanced tissue-biomaterial integration
US8673333B2 (en) 2002-09-25 2014-03-18 The Johns Hopkins University Cross-linked polymer matrices, and methods of making and using same
US20090183270A1 (en) 2002-10-02 2009-07-16 Adams Thomas R Transgenic plants with enhanced agronomic traits
WO2004033631A2 (en) 2002-10-04 2004-04-22 Regents Of The University Of Minnesota Nucleic acid and polypeptide sequences from lawsonia intracellularis and methods of using
US20050069572A1 (en) 2002-10-09 2005-03-31 Jennifer Elisseeff Multi-layered polymerizing hydrogels for tissue regeneration
FR2846659B1 (en) 2002-10-30 2005-02-18 Centre Nat Rech Scient PEPTIDE FRAGMENTS OF THE HARP FACTOR INHIBITING ANGIOGENESIS
EP1570270A4 (en) 2002-11-15 2010-09-22 Univ Arizona Therapeutic bioconjugates
JP2006523681A (en) 2003-03-24 2006-10-19 ルイトポルド・ファーマシューティカルズ・インコーポレーテッド Xanthone, thioxanthone and acridinone as DNA-PK inhibitors
US8198020B2 (en) 2003-08-22 2012-06-12 Potentia Pharmaceuticals, Inc. Compositions and methods for enhancing phagocytosis or phagocyte activity
FR2861308A1 (en) 2003-10-28 2005-04-29 Organes Tissus Regeneration Re Using carboxylated and sulfonated biocompatible polymers in pharmaceutical, dermatological or cosmetic compositions, for control of discomfort, disorders and pain, e.g. sunburn
EP1677807B1 (en) 2003-10-28 2010-09-08 Organes, Tissus : Régénération, Réparation, Remplacement-OTR3 Use of biocompatible polymers for the preparation of a composition or a medical device
EP1694247A2 (en) 2003-12-15 2006-08-30 Technion Research And Development Foundation, Ltd. Therapeutic drug-eluting endoluminal covering
WO2005061018A1 (en) 2003-12-22 2005-07-07 Regentis Biomaterials Ltd. Matrix comprising naturally-occurring protein backbone
US7842667B2 (en) 2003-12-22 2010-11-30 Regentis Biomaterials Ltd. Matrix composed of a naturally-occurring protein backbone cross linked by a synthetic polymer and methods of generating and using same
US7709439B2 (en) 2004-02-20 2010-05-04 Boston Scientific Scimed, Inc. Biomaterials for enhanced healing
US20060041961A1 (en) 2004-03-25 2006-02-23 Abad Mark S Genes and uses for pant improvement
WO2005116066A1 (en) 2004-05-31 2005-12-08 National University Of Singapore Peptides derived from decorin leucine rich repeats and uses thereof
US20060075522A1 (en) 2004-07-31 2006-04-06 Jaclyn Cleveland Genes and uses for plant improvement
WO2006036681A2 (en) 2004-09-22 2006-04-06 Cartilix, Inc. Cartilage filling device
JP5042025B2 (en) 2004-09-29 2012-10-03 ナショナル ユニヴァーシティー オブ シンガポール COMPOSITE, COMPOSITE MANUFACTURING METHOD, AND USE THEREOF
US20060241022A1 (en) 2004-10-06 2006-10-26 Bowen Benjamin P Selectin targeting bioconjugates
WO2006047758A1 (en) 2004-10-27 2006-05-04 Massachusetts Institute Of Technology Novel technique to fabricate molded structures having a patterned porosity
WO2007044026A2 (en) 2004-11-23 2007-04-19 The Johns Hopkins University Compositions comprising modified collagen and uses therefore
WO2006089119A2 (en) 2005-02-18 2006-08-24 Cartilix, Inc. Biological adhesive
WO2006089167A1 (en) 2005-02-18 2006-08-24 Cartilix, Inc. Glucosamine materials
KR20070108555A (en) 2005-03-04 2007-11-12 노오쓰웨스턴 유니버시티 Angiogenic heparin binding peptide amphiphiles
GB2424223C (en) 2005-03-07 2011-02-02 Massachusetts Inst Technology Biomaterial.
US8431226B2 (en) 2005-03-30 2013-04-30 Biomet Manufacturing Corp. Coated medical device
US7732427B2 (en) 2005-03-31 2010-06-08 University Of Delaware Multifunctional and biologically active matrices from multicomponent polymeric solutions
US8415325B2 (en) 2005-03-31 2013-04-09 University Of Delaware Cell-mediated delivery and targeted erosion of noncovalently crosslinked hydrogels
US7737131B2 (en) 2005-03-31 2010-06-15 University Of Delaware Multifunctional and biologically active matrices from multicomponent polymeric solutions
US8367639B2 (en) 2005-03-31 2013-02-05 University Of Delaware Hydrogels with covalent and noncovalent crosslinks
US8338390B2 (en) 2005-03-31 2012-12-25 University Of Delaware Multifunctional and biologically active matrices from multicomponent polymeric solutions
EP2478760A1 (en) 2005-05-10 2012-07-25 Monsanto Technology LLC Genes and uses for plant improvement
WO2006130974A1 (en) 2005-06-08 2006-12-14 Cangene Corporation Hyaluronic acid binding peptides enhance host defense against pathogenic bacteria
US20080069774A1 (en) 2005-11-17 2008-03-20 Lance Liotta Proteomic antisense molecular shield and targeting
JP2009529374A (en) 2006-03-07 2009-08-20 アクスル インターナショナル Bioactive scaffolds for treatment and adhesion prevention
US20070212385A1 (en) 2006-03-13 2007-09-13 David Nathaniel E Fluidic Tissue Augmentation Compositions and Methods
JP2009529967A (en) 2006-03-15 2009-08-27 サーモディクス,インコーポレイティド Hydrophobic derivatives of natural biodegradable polysaccharides and their use
CA2644273A1 (en) 2006-04-05 2008-03-27 Metanomics Gmbh Process for the production of a fine chemical
GB0610395D0 (en) 2006-05-25 2006-07-05 Ge Healthcare Ltd Novel imaging agents
US20090162436A1 (en) 2006-06-14 2009-06-25 Carson Daniel D Compositions and methods for repair of tissues
SI2484375T1 (en) 2006-09-26 2018-08-31 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US7592009B2 (en) * 2006-10-10 2009-09-22 Ecole Polytechnique Federale De Lausanne (Epfl) Polypeptide ligands for targeting cartilage and methods of use thereof
US8114834B2 (en) 2006-11-09 2012-02-14 Northwestern University Self-assembling peptide amphiphiles
US8114835B2 (en) 2006-11-09 2012-02-14 Northwestern University Self-assembling peptide amphiphiles for tissue engineering
US20100222546A1 (en) 2006-11-28 2010-09-02 David Crich Methods for the preparation of functionalized peptides, proteins and carbohydrates and their conjugates
US20080295196A1 (en) 2006-12-06 2008-11-27 Abad Mark S Genes and uses for plant improvement
WO2008136869A2 (en) 2006-12-06 2008-11-13 Burnham Institute For Medical Research Methods and compositions related to targeting wounds, regenerating tissue, and tumors
ES2596707T3 (en) 2007-04-16 2017-01-11 Regentis Biomaterials Ltd. Compositions and methods for frame formation
US20100119577A1 (en) 2007-05-06 2010-05-13 Byoung-Hyun Min Therapeutic composite for cartilage disorder using extracellular matrix (ecm) scaffold
WO2008152639A2 (en) 2007-06-12 2008-12-18 Bypass, Inc. Pressure pulse actuating device for delivery systems
US20090075281A1 (en) 2007-07-10 2009-03-19 Regents Of The University Of California Mtbe genes
US7993679B2 (en) 2007-09-25 2011-08-09 Integra Lifesciences Corporation Flowable wound matrix and its preparation and use
WO2009048280A2 (en) 2007-10-09 2009-04-16 Postech Academy-Industry Foundation Long acting hyaluronic acid - peptide conjugate
WO2009099580A2 (en) 2008-02-05 2009-08-13 Monsanto Technology, Llc Isolated novel nucleic acid and protein molecules from soy and methods of using those molecules to generate transgenic plants with enhanced agronomic traits
DK2280720T3 (en) 2008-03-27 2019-06-11 Purdue Research Foundation COLLAGEN BINDING SYNTHETIC PEPTIDOGLYCANES, MANUFACTURING AND PROCEDURE FOR USE
KR101594552B1 (en) 2008-04-04 2016-02-17 유니버시티 오브 유타 리서치 파운데이션 Alkylated sem-synthetic glycosaminoglycosan ethers, and methods for making and using thereof
US8343942B2 (en) 2008-04-04 2013-01-01 University Of Utah Research Foundation Methods for treating interstitial cystitis
US20100004196A1 (en) 2008-06-17 2010-01-07 Hopitaux Universitaires De Geneve Heparan sulfate proteoglycan composition and use thereof
WO2010011857A2 (en) 2008-07-23 2010-01-28 The Johns Hopkins University Parenteral administration of a glucosamine
WO2010019769A1 (en) 2008-08-15 2010-02-18 The Trustees Of The University Of Pennsylvania Cross-linked polymer network formed by sequential cross-linking
BRPI0918621A2 (en) 2008-09-17 2015-08-25 Ceres Inc Transgenic plants with increased biomass
FR2936247B1 (en) 2008-09-24 2010-10-22 Ct Hospitalier Universitaire De Dijon RECOMBINANT PROTEINS WITH HEMOSTATIC ACTIVITY CAPABLE OF INDUCING PLATELET AGGREGATION.
US9072688B2 (en) 2008-10-31 2015-07-07 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
ES2394897T3 (en) 2008-11-28 2013-02-06 Zetascience Gmbh Bioactive hydrogel
KR101062068B1 (en) 2008-12-01 2011-09-02 포항공과대학교 산학협력단 Anti-adhesion Composition
IL195764A0 (en) 2008-12-07 2009-11-18 Technion Res & Dev Foundation Compositions and methods for drug delivery
US9012723B2 (en) 2009-01-16 2015-04-21 Monsanto Technology Llc Isolated novel acid and protein molecules from soy and methods of using those molecules to generate transgene plants with enhanced agronomic traits
WO2010117694A2 (en) 2009-03-30 2010-10-14 Prometheus Laboratories Inc. Citrullinated peptides for diagnosing and prognosing rheumatoid arthritis
WO2010115156A2 (en) 2009-04-03 2010-10-07 Synthetic Genomics, Inc. Endophytic fungus and uses therefor
KR20120012811A (en) 2009-04-13 2012-02-10 노오쓰웨스턴 유니버시티 Novel peptide-based scaffolds for cartilage regeneration and methods for their use
FI20095452A0 (en) 2009-04-23 2009-04-23 Suomen Punainen Risti Veripalv New Branch Sugar Analysis
WO2010129547A1 (en) 2009-05-04 2010-11-11 Purdue Research Foundation Collagen-binding synthetic peptidoglycans for wound healing
GB0909671D0 (en) 2009-06-04 2009-07-22 Xention Discovery Ltd Compounds
EP2499167A4 (en) 2009-11-09 2013-07-10 Univ Drexel Compositions and methods for treating a disorder or defect in soft tissue
WO2011069046A1 (en) 2009-12-04 2011-06-09 Euclid Systems Corporation Composition and methods for the prevention and treatment of macular degeneration, diabetic retinopathy, and diabetic macular edema
DK2513294T3 (en) 2009-12-16 2016-06-06 Regentis Biomaterials Ltd SKELETS FOR POLYMER-PROTEIN CONJUGATES, PROCEDURES FOR GENERATION THEREOF AND APPLICATIONS THEREOF
EP2528437A4 (en) 2010-01-26 2013-10-02 Univ Utah Res Found Methods for treating or preventing the spread of cancer using semi-synthetic glycosaminoglycosan ethers
EP2538957B1 (en) 2010-02-26 2019-07-24 Vascular Biosciences, Inc. Car peptide for homing, diagnosis,&targeted therapy for pulmonary and fibrotic disorders
EP2585112B1 (en) 2010-06-23 2019-05-15 Purdue Research Foundation Collagen-binding synthetic peptidoglycans for use in vascular intervention
US9173919B2 (en) 2011-02-16 2015-11-03 Purdue Research Foundation Collagen-targeted nanoparticles
US20130101628A1 (en) 2011-04-29 2013-04-25 Northwestern University Novel vegf mimetic peptide-based scaffolds for therapeutic angiogenesis and methods for their use
KR102006036B1 (en) 2011-05-24 2019-07-31 시믹 아이피, 엘엘씨 Hyaluronic acid-binding synthetic peptidoglycans, preparation, and methods of use
EP2804586A4 (en) 2012-01-19 2016-03-16 Univ Johns Hopkins Biomaterials comprising hyaluronic acid binding peptides and bifunctional biopolymer molecules for hyaluronic acid retention and tissue engineering applications
US9540428B2 (en) 2012-07-03 2017-01-10 Ecole Polytechnique Federale De Lausanne (Epfl) Extracellular matrix heparin-binding domains
US9827321B2 (en) 2012-08-14 2017-11-28 The Trustees Of The University Of Pennsylvania Stabilizing shear-thinning hydrogels
WO2014038866A1 (en) 2012-09-05 2014-03-13 아주대학교산학협력단 Composition for treating angiogenic diseases using extracellular matrix membrane of cartilage-derived cell, and transplant material for cornea or conjunctiva
DE102012108560B4 (en) 2012-09-13 2018-12-20 Leibniz-Institut Für Polymerforschung Dresden E.V. Noncovalent self-assembling hydrogel matrix for biotechnological applications
CN104870020A (en) 2012-10-19 2015-08-26 康奈尔大学 Biomimetic boundary lubricants for articular cartilage
WO2014071132A1 (en) 2012-11-01 2014-05-08 The Johns Hopkins University Contact lens surface modification with hyaluronic acid (ha) binding peptide for ha accumulation and retention
WO2014099997A1 (en) 2012-12-18 2014-06-26 Novartis Ag Compositions and methods that utilize a peptide tag that binds to hyaluronan
JP6603650B2 (en) 2013-03-15 2019-11-06 パーデュー・リサーチ・ファウンデーション Extracellular matrix-bound synthetic peptidoglycan
JP6226305B2 (en) 2013-04-16 2017-11-08 パナソニックIpマネジメント株式会社 Power conversion device, power conversion method, and motor system
WO2015022326A1 (en) 2013-08-12 2015-02-19 Xiber Science Gmbh Peptides as active agents for treating primary graft dysfunction
DE102013113156A1 (en) 2013-11-28 2015-05-28 Freie Universität Berlin A compound and method for selectively radiolabeling polypeptides by solid phase synthesis
US10772931B2 (en) 2014-04-25 2020-09-15 Purdue Research Foundation Collagen binding synthetic peptidoglycans for treatment of endothelial dysfunction
CN106714820A (en) 2014-05-12 2017-05-24 普渡研究基金会 Selectin and icam/vcam peptide ligand conjugates
WO2016061147A1 (en) 2014-10-13 2016-04-21 John Eric Paderi Luminal vessel coating for arteriovenous fistula
WO2016061145A1 (en) 2014-10-13 2016-04-21 Symic Biomedical, Inc. Synthetic proteoglycans for preventing tissue adhesion
WO2016065083A1 (en) 2014-10-21 2016-04-28 Symic Biomedical, Inc. Peptidoglycans comprising collagen-binding peptides for treating gastroesophageal injury
WO2016161333A2 (en) 2015-04-01 2016-10-06 Purdue Research Foundation Compositions comprising bioconjugates
KR20180016988A (en) 2015-04-17 2018-02-20 시믹 아이피, 엘엘씨 Bio conjugates and uses thereof
WO2017066349A1 (en) 2015-10-13 2017-04-20 Symic Ip, Llc Ve-cadherin binding bioconjugate

Also Published As

Publication number Publication date
JP6603650B2 (en) 2019-11-06
EP2970509B1 (en) 2020-05-13
AU2014233537A1 (en) 2015-09-10
US20160129076A1 (en) 2016-05-12
CA2903450A1 (en) 2014-09-18
EP2970509A1 (en) 2016-01-20
US9872887B2 (en) 2018-01-23
WO2014144969A1 (en) 2014-09-18
MX2015012608A (en) 2016-07-06
JP2016516065A (en) 2016-06-02
US20190022175A1 (en) 2019-01-24
ZA201506391B (en) 2017-09-27
EP2970509A4 (en) 2016-11-02
US20140288002A1 (en) 2014-09-25
IL241054A0 (en) 2015-11-30
KR20150130419A (en) 2015-11-23
BR112015022917A2 (en) 2017-07-18
US9200039B2 (en) 2015-12-01
EA201591454A1 (en) 2015-12-30
HK1220217A1 (en) 2017-04-28

Similar Documents

Publication Publication Date Title
HK1220217A1 (en) Extracellular matrix-binding synthetic peptidoglycans
GB201317887D0 (en) Product
GB201413149D0 (en) No details
GB201305668D0 (en) Avs6 Integrin Antagonists
SG2013046479A (en) Bio-based synthetic fluids
GB201506699D0 (en) No details
GB201410903D0 (en) No details
GB201321785D0 (en) Route Monitoring
GB201421649D0 (en) No details
GB201418212D0 (en) No details
GB201418129D0 (en) No details
GB201421548D0 (en) No details
GB201408089D0 (en) No details
GB201418214D0 (en) No details
GB201416327D0 (en) No details
GB201407200D0 (en) No details
GB201312729D0 (en) Cleaning product
GB201417843D0 (en) No details
GB2530230B (en) Voltage-limiter monitoring
GB201311769D0 (en) Product
GB201302290D0 (en) Cleaning product
GB201322936D0 (en) Polyurethane
GB201500998D0 (en) No details
GB2509781B (en) Transmitter
GB201316462D0 (en) Creating reports